Product Information
PROPYLTHIOURACIL 50 MG TABLET is a generic product labeled by Quagen Pharmaceuticals LLC, priced at $0.2687 per EA under NDC 70752017110. Its NADAC has been published 282 times since May 12, 2021.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is BD.
Strength
50 mg/1
Manufacturer
Quagen Pharmaceuticals LLCNDC
70752017110
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PROPYLTHIOURACILApproval Type
Generic (ANDA)
FDA Application
ANDA080154FDA Approved
Before 1982
TE Code
BD
On Market Since
3/18/2021
Pharmacological Classes
Price Statistics
The NADAC for PROPYLTHIOURACIL 50 MG TABLET has been published 282 times since May 12, 2021, and over the history we have for it it has declined 45.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2687 per EA |
|---|---|
| All-time high | $0.5497 (Aug 11, 2021) |
| All-time low | $0.2149 (May 22, 2024) |
| 52-week high | $0.3044 |
| 52-week low | $0.2646 |
| Median price | $0.3504 |
| Average price | $0.3756 |
| Largest weekly change | -44.1% (May 22, 2024) |
| Weeks tracked | 282 |
| Tracking since | May 12, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PROPYLTHIOURACIL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quagen Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PROPYLTHIOURACIL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Thyroid Hormone Synthesis Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROPYLTHIOURACIL 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PROPYLTHIOURACIL 50 MG TABLET, manufactured by Quagen Pharmaceuticals LLC, is $0.2687 per EA (NDC 70752017110), effective Sep 30, 2026.
How has the price of PROPYLTHIOURACIL 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for PROPYLTHIOURACIL 50 MG TABLET has declined 45.2%. It has been tracked across 282 weekly CMS publications since May 12, 2021.
What are the highest and lowest recorded NADAC prices for PROPYLTHIOURACIL 50 MG TABLET?
Since May 12, 2021, the NADAC for PROPYLTHIOURACIL 50 MG TABLET has ranged from a low of $0.2149 (May 22, 2024) to a high of $0.5497 (Aug 11, 2021), with a median of $0.3504 per EA.
Are there cheaper alternatives to PROPYLTHIOURACIL 50 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PROPYLTHIOURACIL 50 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PROPYLTHIOURACIL 50 MG TABLET?
PROPYLTHIOURACIL 50 MG TABLET (NDC 70752017110) is labeled by Quagen Pharmaceuticals LLC, and CMS classifies it as a generic product.